Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus,
AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour o
Australia's CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other re
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosi
Hard on the heels of the official launch of its digital disease management platform, Aptar Pharma has secured a partnership with Italian drugmaker Chiesi to deploy it in support of patients
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.